Conatus gains on publication of NASH med data

Conatus Pharmaceuticals (NASDAQ:CNAT) is up 6% premarket on light volume on the heels of the publication of results from three previously reported mid-stage studies of lead drug emirasan in NAFLD/NASH, portal hypertension and liver cirrhosis.

Three Phase 2b studies are in process with collaboration partner Novartis: ENCORE-NF (NASH) (topline data expected in H1); ENCORE-PH (portal hypertension) (clinical outcome data expected mid-year) and ENCORE-LF (liver function) (topline data expected mid-year).

https://seekingalpha.com/news/3426358-conatus-6-percent-premarket-publication-emricasan-data